Complex Regional Pain Syndrome Clinical Trials

Find Complex Regional Pain Syndrome Clinical Trials Near You

A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE)

Status: Recruiting
Location: See all (26) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female participant ≥ 18 years of age at time of Screening.

• A diagnosis of CRPS-1 according to the clinical Budapest Criteria as recommended by the International Association for the Study of Pain (IASP), as well as no known peripheral nerve injury. Signs and symptoms of CRPS must apply to a single identified affected limb (i.e., arm, hand, wrist, leg, ankle or foot) and must demonstrate asymmetry with respect to the contralateral limb.

• Single affected limb at the Screening and Randomization Visits meeting the following warm subtype criteria:

‣ Edema in the affected limb

⁃ AND ≥ 2 of the following:

• Obvious redness in the affected region relative to the same region on the contralateral limb on inspection

∙ ≥ 1°C increase in temperature on the affected limb relative to the contralateral limb

∙ Moderate-to-severe edema

• ≤ 6 months since the onset of CRPS symptoms relative to the Randomization visit

• Increased uptake in the involved limb compared to the contralateral limb on TPBS (phase 2 and/or phase 3) during Screening. A historic scan not older than 3 months prior to Randomization Visit is acceptable, if available and of sufficient quality for a central read.

• Women of childbearing potential must:

‣ Be nonpregnant.

⁃ Be nonlactating.

⁃ Agree to use a highly effective method of contraception and for at least 6 months following last investigational product administration.

• Exception: Women exclusively engaging in same sex sexual activities are not required to meet this criterion.

• Adequate compliance with the eDiary during the screening period.

Locations
United States
Arkansas
Ambros Clinical Trial Site
RECRUITING
Little Rock
Arizona
Ambros Clinical Trial Site
RECRUITING
Phoenix
Ambros Clinical Trial Site
RECRUITING
Tucson
California
Ambros Clinical Trial Site
RECRUITING
La Jolla
Ambros Clinical Trial Site
RECRUITING
Napa
Ambros Clinical Trial Site
RECRUITING
Pasadena
Ambros Clinical Trial Site
RECRUITING
Tustin
Washington, D.c.
Ambros Clinical Trial Site
RECRUITING
Washington D.c.
Florida
Ambros Clinical Trial Site
RECRUITING
Brandon
Ambros Clinical Trial Site
RECRUITING
Daytona Beach
Ambros Clinical Trial Site
RECRUITING
Pembroke Pines
Georgia
Ambros Clinical Trial Site
RECRUITING
Lawrenceville
Ambros Clinical Trial Site
RECRUITING
Newnan
Illinois
Ambros Clinical Trial Site
RECRUITING
Orland Park
Kansas
Ambros Clinical Trial Site
RECRUITING
Overland Park
North Carolina
Ambros Clinical Trial Site
RECRUITING
Charlotte
Ambros Clinical Trial Site
RECRUITING
Wilmington
Ambros Clinical Trial Site
RECRUITING
Winston-salem
New Jersey
Ambros Clinical Trial Site
RECRUITING
Shrewsbury
Nevada
Ambros Clinical Trial Site
RECRUITING
Reno
Ohio
Ambros Clinical Trial Site
RECRUITING
Dayton
Texas
Ambros Clinical Trial Site
RECRUITING
Fort Worth
Ambros Clinical Trial Site
RECRUITING
Houston
Ambros Clinical Trial Site
RECRUITING
Lubbock
Ambros Clinical Trial Site
RECRUITING
Mesquite
Virginia
Ambros Clinical Trial Site
RECRUITING
Charlottesville
Contact Information
Primary
SVP, Clinical Operations
clinicaltrials@ambrostx.com
+1 949-785-4954
Backup
Ambros Therapeutics, Inc
Time Frame
Start Date: 2026-04-14
Estimated Completion Date: 2028-01
Participants
Target number of participants: 270
Treatments
Experimental: neridronate
400 mg AMBTX-01 infusion
Placebo_comparator: Placebo
Placebo comparator
Related Therapeutic Areas
Sponsors
Leads: Ambros Therapeutics, Inc.

This content was sourced from clinicaltrials.gov